⚠ Evidence warning: Clinical trials or other evidence do not support the claims that L-tryptophan supplements ease mild depression, carbohydrate craving and anxiety. This page keeps it as a report of what people, websites or other media say.
Tryptophan for Mood and Serotonin
Tryptophan is the unique dietary precursor of serotonin, the master mood neurotransmitter. The rate-limiting enzyme for brain serotonin synthesis is tryptophan hydroxylase 2 (TPH2), distinct from its peripheral cousin TPH1. Substrate availability matters: the acute tryptophan depletion (ATD) method, reported in healthy men by Young and colleagues in 1985, was applied by Delgado and colleagues in 1990 to patients in remission on antidepressants: depleting plasma tryptophan with a low-tryptophan diet and an amino-acid drink lacking tryptophan rapidly brought depressive relapse in 14 of 21 patients while they were still taking their antidepressants. This work has been used as direct human evidence for the serotonin hypothesis of depression, a hypothesis a 2022 umbrella review found no consistent support for. The flip side — that supplemental tryptophan or 5-HTP can ameliorate mood — is real but more modest, partly because tryptophan competes with the branched-chain amino acids (leucine, isoleucine, valine) for the blood-brain barrier LAT1 transporter, and partly because the kynurenine pathway captures ~95% of dietary tryptophan before any of it reaches the serotonin pool. This page walks through the TPH2 biology, the ATD experiment, the carbohydrate-insulin-BCAA-clearance trick that opens the BBB to tryptophan, and the practical comparison with selective serotonin reuptake inhibitors and with 5-HTP.
Table of Contents
- TPH2 — The Brain's Rate-Limiting Enzyme for Serotonin
- TPH1 vs TPH2 — Why the Gut and Brain Are Separate Systems
- Crossing the Blood-Brain Barrier via LAT1
- The Carbohydrate-Insulin-BCAA-Clearance Trick
- The Acute Tryptophan Depletion (ATD) Paradigm
- Delgado 1990 — Tryptophan Depletion Reverses Antidepressant Remission
- Comparison with Selective Serotonin Reuptake Inhibitors
- Comparison with 5-HTP
- Practical Clinical Applications
- Cautions and Serotonin Syndrome
- Key Research Papers
- Connections
- Featured Videos
TPH2 — The Brain's Rate-Limiting Enzyme for Serotonin
Tryptophan hydroxylase is the enzyme that takes L-tryptophan and adds a hydroxyl group to position 5 of its indole ring, yielding 5-hydroxytryptophan (5-HTP). It is the slowest step in the whole tryptophan-to-serotonin pipeline, making it the rate-limiting enzyme. Tryptophan hydroxylase requires three cofactors: tetrahydrobiopterin (BH4), molecular oxygen, and iron at the active site.
For decades, tryptophan hydroxylase was treated as a single enzyme. In 2003, Walther and colleagues at the Max Delbruck Center in Berlin reported the unexpected discovery that vertebrates have two distinct tryptophan hydroxylase genes: TPH1, expressed almost exclusively in peripheral tissues (gut enterochromaffin cells, pineal gland, skin), and TPH2, expressed almost exclusively in the brain's serotonergic neurons of the raphe nuclei. The two enzymes have similar catalytic mechanisms but distinct gene regulation, distinct subcellular localization, and distinct sensitivity to substrate availability.
The TPH2 discovery was a major event in mood-disorder neuroscience because it meant that brain serotonin and gut serotonin are biochemically independent. The enzyme that makes brain serotonin is a different protein than the enzyme that makes gut serotonin. This explains why peripheral measures of serotonin (platelet uptake, urinary 5-HIAA, gut motility) have proven so unreliable as proxies for brain serotonin status and why pharmacologic manipulation of one compartment does not automatically affect the other.
TPH2 is not normally saturated with substrate under typical dietary intake. The implication is that substrate availability matters for brain serotonin output. Other rate-limiting enzymes (such as tyrosine hydroxylase, the rate-limiting enzyme of the dopamine pathway; DOPA decarboxylase is a later step) are typically substrate-saturated under physiologic conditions, so providing more substrate does not raise output. TPH2 is the exception: provide more tryptophan to the brain, and you measurably raise serotonin synthesis. Conversely, deplete tryptophan, and serotonin synthesis falls within hours. This biochemical fact is the foundation of both dietary tryptophan augmentation strategies and the acute tryptophan depletion (ATD) experimental paradigm.
TPH1 vs TPH2 — Why the Gut and Brain Are Separate Systems
Approximately 95% of the body's serotonin is made by TPH1 in gut enterochromaffin cells. This peripheral serotonin does important things — it regulates gut motility (the basis of the 5-HT3-antagonist anti-emetic class), platelet aggregation (platelets store but do not synthesize serotonin), bone remodeling (peripheral serotonin inhibits osteoblast proliferation), and inflammatory responses. But peripheral serotonin does not cross the blood-brain barrier in physiologically relevant amounts. The BBB is impermeable to serotonin itself; it is permeable only to tryptophan, the precursor.
This is why measurements of serum or platelet serotonin do not predict mood. It is why selective serotonin reuptake inhibitors work on mood by acting in the brain's serotonergic synapses (TPH2 territory) and do not need to alter gut serotonin (TPH1 territory) to do so. And it is why the older literature describing "serotonin levels" without specifying which compartment is being measured was often confused.
For dietary tryptophan supplementation, the implication is two-fold:
- Some of an oral tryptophan dose will be diverted to gut TPH1 and made into peripheral serotonin. This is the source of the occasional gastrointestinal (GI) side effects (nausea, loose stools) of high-dose tryptophan or 5-HTP supplementation.
- The fraction of an oral dose that actually reaches the brain depends on plasma tryptophan dynamics, competition with other LNAAs at the BBB, and the kynurenine pathway capture in the liver. Roughly 1–3% of an oral tryptophan dose ends up as new brain serotonin in young healthy adults.
Crossing the Blood-Brain Barrier via LAT1
Tryptophan does not freely diffuse across the blood-brain barrier. It is transported by the large neutral amino acid transporter LAT1 (gene symbol SLC7A5), a heterodimer of SLC7A5 and CD98 (4F2hc). LAT1 is highly expressed on both the luminal and abluminal surfaces of brain capillary endothelial cells and on the membranes of neurons and glia.
LAT1 transports several large neutral amino acids that compete with one another for the same carrier:
- Tryptophan
- Tyrosine
- Phenylalanine
- Leucine
- Isoleucine
- Valine
- Methionine
- Histidine
The transporter operates as an obligate exchanger — it moves one amino acid in and one out. Total brain uptake of any individual large neutral amino acid is determined not by its plasma concentration in isolation, but by its ratio to the sum of competing amino acids. This is the Fernstrom-Wurtman tryptophan ratio (plasma tryptophan divided by the sum of plasma valine, leucine, isoleucine, tyrosine, and phenylalanine). If that ratio goes up, brain tryptophan uptake goes up. If it goes down — even if tryptophan itself is unchanged — brain uptake goes down.
This is the molecular basis for the counterintuitive observation that eating protein does not predictably raise brain tryptophan. Mixed-protein foods raise plasma tryptophan, but they raise the competing branched-chain amino acids (BCAAs) more (because tryptophan is the least-abundant essential amino acid in most foods). The ratio goes down, and brain tryptophan uptake actually falls.
The Carbohydrate-Insulin-BCAA-Clearance Trick
Pure carbohydrate ingestion, by contrast, paradoxically raises the brain-tryptophan ratio. The mechanism involves insulin. Carbohydrate triggers insulin release. Insulin powerfully stimulates muscle uptake of the branched-chain amino acids (leucine, isoleucine, valine), which are major fuel substrates for skeletal muscle. The branched-chain amino acids leave the bloodstream rapidly under insulin's influence. Tryptophan, in contrast, is largely bound to plasma albumin (60–80% bound depending on conditions) and is not transported into muscle to nearly the same extent. So insulin preferentially clears the competitors while leaving tryptophan in plasma.
Within 30–90 minutes after a pure-carbohydrate meal, the Fernstrom-Wurtman ratio rises, and brain tryptophan uptake and brain serotonin synthesis are expected to rise with it. The phenomenon was originally demonstrated in rats by Richard Wurtman and John Fernstrom at MIT in the early 1970s (in the rat, injected insulin or a carbohydrate meal raised tryptophan in the plasma and brain, then serotonin in the brain) and has been replicated extensively. In people, a 2003 study by the same MIT group compared normal breakfasts: among the 8 people who ate both a carbohydrate-rich breakfast (69.9 g carbohydrate, 5.2 g protein) and a protein-rich one (15.4 g carbohydrate, 46.8 g protein), the plasma tryptophan ratio differed by a median of 54% (range 36–88%). That study measured blood only; its authors wrote that brain tryptophan and serotonin synthesis "probably" differ too. The phenomenon is offered as the biochemical explanation for several familiar observations:
- Postprandial sleepiness after carb-heavy meals — the rise in brain serotonin (and downstream pineal melatonin output) acutely is part of the cause. This, not turkey-specific tryptophan, is the real mechanism of the Thanksgiving turkey myth.
- Carbohydrate craving in seasonal affective disorder (SAD), premenstrual dysphoric disorder (PMDD), and atypical depression — these subgroups appear to be self-medicating low brain serotonin tone through preferred carbohydrate intake.
- The advice to take L-tryptophan supplements on an empty stomach or with a small carbohydrate, not with a protein meal — this maximizes the ratio and the effective brain delivery.
- The complaint of mood disturbance on strict low-carbohydrate diets — brain tryptophan and serotonin tone drop measurably on very-low-carb diets, especially in the first weeks.
Practitioners apply this to the timing of tryptophan supplements: they describe taking L-tryptophan 30–60 minutes before bed on an empty stomach with a small carbohydrate (a banana, half a slice of bread with honey, a small glass of orange juice), with no protein for at least 90 minutes either side.
The Acute Tryptophan Depletion (ATD) Paradigm
The acute tryptophan depletion experiment is one of the most elegant pieces of human neuroscience and has been used as direct evidence for a causal role of brain serotonin in mood regulation.
The protocol exploits the same LAT1 transporter competition described above, but in reverse. Subjects are given an amino-acid drink containing all of the large neutral amino acids except tryptophan. The high load of competing LNAAs has two effects:
- It drives competing amino acids into muscle and tissue protein synthesis, raising their plasma concentrations dramatically.
- The same protein synthesis pulls free tryptophan out of the plasma pool because tissue protein synthesis demands tryptophan along with all other amino acids. Plasma tryptophan can fall by 75–85% within 4–6 hours.
The combined effect collapses the Fernstrom-Wurtman ratio to near zero. Brain tryptophan uptake essentially stops. Brain serotonin synthesis halts within hours. By 5–7 hours after the drink, brain serotonin tone has dropped substantially, and the mood and cognitive consequences become measurable.
The procedure is reversible. A normal meal containing tryptophan within 24 hours restores plasma tryptophan and brain serotonin to baseline. ATD is therefore a temporary, controlled, recoverable experimental manipulation of one neurotransmitter system in awake humans — an extraordinarily powerful tool that the field has used since at least 1985, when Young and colleagues published it in healthy men, to test the serotonin hypothesis of mood disorders directly.
Delgado 1990 — Tryptophan Depletion Reverses Antidepressant Remission
The most consequential ATD experiment was reported by Pedro Delgado and colleagues at Yale in Archives of General Psychiatry in 1990. They studied 21 patients with major depressive disorder who had achieved remission on antidepressants and were still taking them. The patients followed a 24-hour low-tryptophan diet (160 mg a day) and were given the ATD amino acid drink the next morning, in a double-blind, placebo-controlled crossover design (each patient served as their own control with a balanced placebo amino-acid mixture containing tryptophan).
The result was dramatic: 14 of the 21 patients (67%) experienced a complete or partial relapse of depressive symptoms within hours of the tryptophan-depleting drink. Hamilton Depression Rating Scale scores rose substantially within the same day. The relapses were transient — patients gradually returned to the remitted state over 24 to 48 hours once back on regular food — but they were unmistakable. Patients who had been clinically well became transiently and unmistakably depressed by removing tryptophan from the substrate pool.
Subsequent ATD studies expanded the picture:
- The effect was much stronger in patients who had recovered on serotonergic antidepressants (selective serotonin reuptake inhibitors, tricyclic antidepressants (TCAs) with serotonergic action) than in patients who had recovered on noradrenergic antidepressants (desipramine). This was consistent with serotonin being the relevant active mechanism for the selective serotonin reuptake inhibitor (SSRI) patients. In a 1999 study by Delgado's group, patients randomly assigned to one drug or the other gave the clearest numbers: 8 of 15 fluoxetine responders relapsed during depletion, against 1 of 15 desipramine responders.
- The effect was modest or absent in never-depressed healthy controls, indicating that low brain serotonin tone is sufficient to precipitate depression in patients with the disorder's underlying biology but not enough to produce de novo depression in resilient individuals.
- The idea has been put forward that the effect is strongest in patients with a family history of mood disorders and in patients with high pre-treatment depression severity, and that serotonin-tone sensitivity is a stable trait marker. A 2002 pooled analysis of individual patient data from six depletion studies (Booij and colleagues) named different predictors: recurrent depressive episodes, female gender, prior exposure to selective serotonin reuptake inhibitors, and previous serious suicidal thoughts or attempts, with chronicity of illness the most powerful. Residual symptoms did not predict a mood response.
The Delgado experiment did not prove the simple "serotonin deficiency causes depression" hypothesis. Its authors concluded that the therapeutic effects of some antidepressant drugs may depend on serotonin availability. It has also been read as establishing that serotonin tone is a causally necessary input to mood maintenance in vulnerable individuals. This is a weaker claim than the simple hypothesis, and it is not a settled consensus.
A 2022 umbrella review (Moncrieff and colleagues, 17 studies) reported that the main areas of serotonin research give no consistent evidence of an association between serotonin and depression, and no support for the idea that depression is caused by lowered serotonin activity or concentrations. On depletion studies specifically, one meta-analysis it included found no effect in most healthy volunteers (566 people) and weak evidence of an effect in volunteers with a family history of depression (75 people). The review also notes that no systematic review of depletion studies has been done since 2007. These depletion figures concern volunteers, not patients in remission on antidepressants like those Delgado studied. The review drew a series of published replies in the same journal.
Comparison with Selective Serotonin Reuptake Inhibitors
Selective serotonin reuptake inhibitors (fluoxetine, sertraline, escitalopram, citalopram, paroxetine, fluvoxamine) block the serotonin reuptake transporter (SERT), raising synaptic serotonin concentrations by preventing presynaptic reuptake. They do not change serotonin synthesis or substrate availability. The therapeutic effect typically takes 3–6 weeks to emerge, attributed to downstream neuroplastic changes (brain-derived neurotrophic factor (BDNF) upregulation, dendritic spine remodeling, hippocampal neurogenesis) rather than the immediate pharmacology.
Tryptophan supplementation, by contrast, raises substrate availability for new serotonin synthesis. The dose-response is shallow (because TPH2 and the kynurenine pathway both buffer the effect), the onset is more gradual, and the magnitude of effect in moderate-to-severe major depression is small in head-to-head comparisons with selective serotonin reuptake inhibitors. 5-HTP and L-tryptophan are often described as having a small but measurable antidepressant effect in mild-to-moderate depression, and the studies have not produced regulatory drug approval. The 2002 Shaw Cochrane review located 108 trials, of which only 2, with 64 patients in total, were of sufficient quality to include. In people with unipolar depression or dysthymia, the available evidence suggested these substances were better than placebo (Peto odds ratio 4.10, 95% confidence interval 1.28–13.15; number needed to treat 2.78), but the reviewers judged the evidence of insufficient quality to be conclusive, and wrote that the possible link between these substances and the potentially fatal eosinophilia-myalgia syndrome has not been elucidated.
A common clinical framing is:
- Selective serotonin reuptake inhibitors are first-line for moderate-to-severe major depression. The evidence base is overwhelmingly larger and the effect size is larger.
- Tryptophan and 5-HTP have a role in mild depression, in subclinical mood disturbance, and as adjuncts, particularly for patients who decline pharmaceutical antidepressants or who have responded incompletely to other interventions.
- Tryptophan is not a substitute for selective serotonin reuptake inhibitors in severe depression with suicidality. Underdosed substrate augmentation can be dangerous in that setting because it may delay effective treatment.
- Combining tryptophan or 5-HTP with a selective serotonin reuptake inhibitor carries a risk of serotonin syndrome, a toxic excess of serotonin. See Cautions below.
For more on the broader management of depression, see Depression. For anxiety see Anxiety.
Comparison with 5-HTP
5-HTP and L-tryptophan are both serotonin precursors, but they enter the pathway at different points and behave differently in practice:
- 5-HTP bypasses TPH2 — the rate-limiting enzyme is already past. This means 5-HTP can produce a faster and steeper rise in serotonin per milligram of dose. Typical effective dose is 50–300 mg compared to 500–2000 mg for L-tryptophan.
- 5-HTP is decarboxylated by AADC peripherally and centrally. AADC is not BBB-restricted (it is expressed throughout peripheral tissues including the gut wall, the liver, and the kidneys). This means a substantial fraction of an oral 5-HTP dose is converted to serotonin in the gut, never reaches the brain, and contributes to gastrointestinal side effects (nausea, vomiting, loose stools at higher doses).
- 5-HTP does not get diverted into the kynurenine pathway — it is committed to the serotonin/melatonin branch once 5-hydroxylated. L-tryptophan, by contrast, gets diverted to kynurenine at the ~95% rate.
- 5-HTP is theoretically more likely to disturb the dopamine/serotonin balance if used long-term without concurrent dopamine precursor (tyrosine or DOPA) support. AADC handles both 5-HTP and L-DOPA. Flooding it with 5-HTP could shift the AADC pool toward serotonin production at the expense of dopamine production in some tissue compartments. This has been the theoretical concern that some naturopathic and functional-medicine practitioners cite for preferring L-tryptophan for chronic use.
- 5-HTP comes from Griffonia simplicifolia seed extract, not from bacterial fermentation. Quality varies by manufacturer; reputable products test for and remove plant-source contaminants.
A 2020 systematic review and meta-analysis of 5-HTP in depression (Javelle and colleagues) reported a remission rate of 0.65 (95% confidence interval 0.55–0.78, 13 studies) and a large improvement on depression questionnaires (Hedges' g 1.11). Its authors call the studies, on the whole, relatively weak, and note that few include placebo groups and that treatment length, type of depression, study design and dose all varied.
Clinical preference among integrative practitioners has historically favored L-tryptophan for long-term mood support (gentler, more physiologic, broader metabolic contribution) and 5-HTP for short-term or acute interventions where rapid effect matters (acute mood drop, sleep onset crisis, time-limited PMDD).
Practical Clinical Applications
- Mild-to-moderate depression in adults declining selective serotonin reuptake inhibitor therapy — practitioners describe L-tryptophan 1000–2000 mg/day divided between evening (sleep) and mid-day (mood) doses, with vitamin B6 (10–25 mg pyridoxal-5-phosphate), magnesium 200–400 mg, and a B-complex for cofactor availability for TPH2 and AADC.
- Premenstrual dysphoric disorder (PMDD) — L-tryptophan or 5-HTP dosed during the luteal phase (the two weeks before a period) is described as having the strongest evidence in mild-to-moderate PMDD; practitioners add vitamin B6 and calcium 1000 mg/day. The placebo-controlled trial (Steinberg 1999, 37 patients on L-tryptophan, 34 on placebo) used L-tryptophan 6 g per day, far above the other doses on this page, for 17 days of each cycle over three cycles. The peak late-cycle mood score fell 34.5% on L-tryptophan and 10.4% on placebo. That trial did not test 5-HTP.
- Seasonal affective disorder (SAD) — L-tryptophan or 5-HTP can be used as augmentation to bright light therapy. Light therapy is the first-line intervention; supplementation is adjunctive. The study behind this (Lam 1997) was open-label, with no placebo group: people who had not fully responded to 2 weeks of light therapy added L-tryptophan 1 g three times daily for 2 weeks. Two of the 16 who started stopped within 3 days because of side effects, and 9 of the 14 who finished showed very good responses. That study did not test 5-HTP.
- Carbohydrate craving and emotional eating — practitioners describe a modest L-tryptophan dose (500–1000 mg) before potentially-triggering meals as reducing craving severity in some patients, and add magnesium and chromium as cofactors for the metabolic component.
- Generalized anxiety with low mood — L-tryptophan has been used as an adjunct to evidence-based interventions (cognitive behavioral therapy (CBT), exercise, sleep optimization). It is not a first-line treatment in moderate-to-severe anxiety.
- Mild postpartum mood disturbance — tryptophan and 5-HTP have been used in research settings, and there is no good safety data on taking them unsupervised in this window. Postpartum mood disorders can turn severe: thoughts of self-harm or of harming the baby, confusion, or hearing and seeing things that are not there are signs hospitals treat as urgent.
A 2021 systematic review (Kikuchi and colleagues) looked at 11 randomized trials of L-tryptophan in healthy adults. Four showed significant differences from the control group on negative and happy feelings; no effect on aggressive feelings was recognized. The authors concluded that 0.14–3 g a day on top of usual meals can be expected to improve mood in healthy people, and that better-designed studies are needed to estimate the amount. These were healthy adults, not people with depression.
Cofactor support is critical and frequently overlooked. TPH2 requires BH4 (downstream of folate metabolism), iron, and molecular oxygen. AADC requires pyridoxal-5-phosphate (active vitamin B6). The downstream serotonin-to-melatonin conversion requires S-adenosylmethionine (SAMe) (methionine cycle), B12, and folate. Patients with anemia (iron-deficient or B12-deficient) or with methylenetetrahydrofolate reductase-related folate cycle inefficiency may not get full benefit from tryptophan supplementation until the cofactor backbone is addressed.
Cautions and Serotonin Syndrome
- Serotonin syndrome — the most consequential interaction. Combining L-tryptophan or 5-HTP with any serotonergic drug can cause serotonin syndrome: agitation, tachycardia, hypertension, hyperthermia, hyperreflexia, clonus, tremor, sweating, mydriasis, autonomic instability, and in severe cases seizures, rhabdomyolysis, disseminated intravascular coagulation (widespread clotting), and death. The classic precipitants are selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, triptans (migraine drugs), tramadol, meperidine, linezolid, methylene blue, dextromethorphan, lithium, and MDMA (ecstasy). High fever, muscle jerks or rigidity, seizures and confusion after such a combination are signs hospitals treat as urgent.
- Children and adolescents — not first-line. Mood symptoms at this age are usually evaluated before any supplement is considered. The U.S. Food and Drug Administration (FDA) Black Box warning on selective serotonin reuptake inhibitors in adolescents reflects the special vulnerability of this age group to medication-related mood and behavioral changes; the same caution has been raised for substrate supplementation.
- Bipolar disorder — tryptophan and 5-HTP can theoretically precipitate hypomanic or manic episodes in patients with bipolar diathesis, just as selective serotonin reuptake inhibitors can. The concern is greatest in unstable bipolar disorder.
- Pregnancy and lactation — insufficient safety data for isolated supplementation; dietary tryptophan comes from normal varied protein intake.
- Carcinoid syndrome — supplementation raises a concern in known serotonin-secreting carcinoid tumors. The dietary precursor will be converted to additional serotonin and worsen flushing, diarrhea, and bronchospasm.
- 1989–1990 eosinophilia-myalgia syndrome (EMS) history — the concern is greatest for patients who had documented EMS from the original L-tryptophan of a Japanese manufacturer, if they resume supplementation. The mechanism of original susceptibility is not fully understood. EMS means muscle pain and high eosinophil counts coming on over weeks, followed by long-lasting nerve damage and hardened skin. The 1989 epidemic was linked to L-tryptophan from a single source; the U.S. Food and Drug Administration banned its sale and cases fell rapidly. The ban was lifted in 2005. A 2011 report said no new cases had been described since then, and described a new one. See the Tryptophan History page for the full EMS history.
- Hepatic and renal impairment — tryptophan metabolism is heavily hepatic. Patients with cirrhosis or significant renal impairment may have altered metabolism, so a usual dose may not behave the same way in them.
Key Research Papers
- Delgado PL et al. (1990). Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Archives of General Psychiatry 47:411–418. — PubMed PMID: 2184795
- Walther DJ et al. (2003). Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299:76. — PubMed PMID: 12511643
- Fernstrom JD, Wurtman RJ (1971). Brain serotonin content: physiological dependence on plasma tryptophan levels. Science 173:149–152. — PubMed PMID: 5581909
- Fernstrom JD, Wurtman RJ (1971). Brain serotonin content: increase following ingestion of carbohydrate diet. Science 174:1023–1025. — PubMed PMID: 5120086
- Young SN et al. (1985). Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 87:173–177. — PubMed PMID: 3931142
- Booij L et al. (2002). Predictors of mood response to acute tryptophan depletion. A reanalysis. Neuropsychopharmacology 27:852–861. — PubMed PMID: 12431859
- Shaw K et al. (2002). Tryptophan and 5-Hydroxytryptophan for depression. Cochrane Database of Systematic Reviews. — PubMed PMID: 11869656
- Markus CR et al. (2000). The bovine protein alpha-lactalbumin increases the plasma ratio of tryptophan to the other large neutral amino acids, and in vulnerable subjects raises brain serotonin activity, reduces cortisol concentration, and improves mood under stress. American Journal of Clinical Nutrition. — PubMed PMID: 10837296
- Steinberg S et al. (1999). A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biological Psychiatry 45:313–320. — PubMed PMID: 10023508
- Lam RW et al. (1997). L-tryptophan augmentation of light therapy in patients with seasonal affective disorder. Canadian Journal of Psychiatry 42:303–306. — PubMed PMID: 9114947
- Boyer EW, Shannon M (2005). The serotonin syndrome. NEJM 352:1112–1120. — PubMed PMID: 15784664
- Delgado PL et al. (1999). Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biological Psychiatry 46:212–220. — PubMed PMID: 10418696
- Wurtman RJ et al. (2003). Effects of normal meals rich in carbohydrates or proteins on plasma tryptophan and tyrosine ratios. American Journal of Clinical Nutrition 77:128–132. — PubMed PMID: 12499331
- Moncrieff J et al. (2023; online 2022). The serotonin theory of depression: a systematic umbrella review of the evidence. Molecular Psychiatry 28:3243–3256. — PubMed PMID: 35854107
- Javelle F et al. (2020). Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis. Nutrition Reviews 78:77–88. — PubMed PMID: 31504850
- Kikuchi AM et al. (2021). A systematic review of the effect of L-tryptophan supplementation on mood and emotional functioning. Journal of Dietary Supplements 18:316–333. — PubMed PMID: 32272859
- Allen JA et al. (2011). Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis and Rheumatism 63:3633–3639. — PubMed PMID: 21702023
- Rao F et al. (2007). Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis: discovery of common human genetic variants governing transcription, autonomic activity, and blood pressure in vivo. Circulation 116:993–1006. — PubMed PMID: 17698732
PubMed Topic Searches
Connections
- All Amino Acids
- Tryptophan Overview
- Tryptophan Benefits Hub
- Tryptophan for Sleep
- Tryptophan and Niacin
- Tryptophan and Cognition
- Depression
- Anxiety
- Insomnia
- Tyrosine (Dopamine Precursor, LNAA Competitor)
- Phenylalanine
- Leucine (Branched-Chain Amino Acid Competitor)
- Isoleucine
- Valine
- Vitamin B6 (AADC Cofactor)
- Magnesium
- History
- Sources